In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer

Clinical Trial ID NCT01923233

Rank	Title	Journal	Year	PubWeight™‹?›
1	Intratumoral immunization: a new paradigm for cancer therapy.	Clin Cancer Res	2014	1.24
2	Allogeneic effector/memory Th-1 cells impair FoxP3+ regulatory T lymphocytes and synergize with chaperone-rich cell lysate vaccine to treat leukemia.	Blood	2010	0.88
3	Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.	World J Hepatol	2015	0.88
4	Th-1 lymphocytes induce dendritic cell tumor killing activity by an IFN-γ-dependent mechanism.	J Immunol	2011	0.87
5	Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma.	J Clin Cell Immunol	2015	0.84
6	Allogeneic CD3/CD28 cross-linked Th1 memory cells provide potent adjuvant effects for active immunotherapy of leukemia/lymphoma.	Leuk Res	2008	0.81
7	The anti-tumor effect of allogeneic bone marrow/stem cell transplant without graft vs. host disease toxicity and without a matched donor requirement?	Med Hypotheses	2007	0.77
8	Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure.	Int J Hyperthermia	2013	0.76
9	Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine.	Int J Hyperthermia	2013	0.76